Using mice to model Alzheimer's dementia: An overview of the clinical disease and the preclinical behavioral changes in 10 mouse models

Frontiers in Genetics

Volumn 5, Issue APR, 2014, Pages

  Webster, Scott J ^a   Bachstetter, Adam D ^a   Nelson, Peter T ^a   Schmitt, Frederick A ^a   Van Eldik, Linda J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

3 TG AD mice; Alzheimer's disease; APP mice; APP PS1 mice; Behavior; Cognition; Mouse models; Neuropsychological assessment

Indexed keywords

AMYLOID PRECURSOR PROTEIN;

3 TG AD MOUSE; 5 FAD MOUSE; AGGRESSION; ALZHEIMER DISEASE; ANXIETY DISORDER; APP PS1 KI MOUSE; APP PS1 MOUSE; APP23 MOUSE; ARTICLE; ATTENTION; BEHAVIOR CHANGE; CIRCADIAN RHYTHM; COGNITIVE DEFECT; DEPRESSION; DISEASE MODEL; EPISODIC MEMORY; EXECUTIVE FUNCTION; EXPERIMENTAL BEHAVIORAL TEST; HUMAN; J20 MOUSE; LEARNING AND MEMORY TEST; LOCOMOTION; MENTAL HEALTH; MOUSE MODEL; MOUSE STRAIN; NEUROPATHOLOGY; NONHUMAN; PDAPP MOUSE; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGIC TEST; TASK PERFORMANCE; TG2576 MOUSE; TGCRND8 MOUSE; WORKING MEMORY;

EID: 84901029497     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2014.00088     Document Type: Article

References (365)

1. Abner, E. L., Kryscio, R. J., Schmitt, F. A., Santacruz, K. S., Jicha, G. A., Lin, Y., et al. (2011). "End-stage" neurofibrillary tangle pathology in preclinical Alzheimer's disease: fact or fiction? J. Alzheimers Dis. 25, 445-453. doi: 10.3233/JAD-2011-101980.
2. Aevarsson, O., and Skoog, I. (2000). A longitudinal population study of the mini-mental state examination in the very old: relation to dementia and education. Dement. Geriatr. Cogn. Disord. 11, 166-175. doi: 10.1159/000017231.
3. Alamed, J., Wilcock, D. M., Diamond, D. M., Gordon, M. N., and Morgan, D. (2006). Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat. Protoc. 1, 1671-1679. doi: 10.1038/nprot.2006.275.
4. Albert, M. S. (1996). Cognitive and neurobiologic markers of early Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 93, 13547-13551. doi: 10.1073/pnas.93.24.13547.
5. Alexander, G., Hanna, A., Serna, V., Younkin, L., Younkin, S., and Janus, C. (2011). Increased aggression in males in transgenic Tg2576 mouse model of Alzheimer's disease. Behav. Brain Res. 216, 77-83. doi: 10.1016/j.bbr.2010.07.016.
6. Ambree, O., Richter, H., Sachser, N., Lewejohann, L., Dere, E., De Souza Silva, M. A., et al. (2009). Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer's disease. Neurobiol. Aging 30, 1192-1204. doi: 10.1016/j.neurobiolaging.2007.11.010.
7. Ambree, O., Touma, C., Gortz, N., Keyvani, K., Paulus, W., Palme, R., et al. (2006). Activity changes and marked stereotypic behavior precede Abeta pathology in TgCRND8 Alzheimer mice. Neurobiol. Aging 27, 955-964. doi: 10.1016/j.neurobiolaging.2005.05.009.
8. Ancoli-Israel, S., Parker, L., Sinaee, R., Fell, R. L., and Kripke, D. F. (1989). Sleep fragmentation in patients from a nursing home. J. Gerontol. 44, M18-M21. doi: 10.1093/geronj/44.1.M18.
9. Angelo, M., Plattner, F., Irvine, E. E., and Giese, K. P. (2003). Improved reversal learning and altered fear conditioning in transgenic mice with regionally restricted p25 expression. Eur. J. Neurosci. 18, 423-431. doi: 10.1046/j.1460-9568.2003.02746.x.
10. Apelt, J., Kumar, A., and Schliebs, R. (2002). Impairment of cholinergic neurotransmission in adult and aged transgenic Tg2576 mouse brain expressing the Swedish mutation of human beta-amyloid precursor protein. Brain Res. 953, 17-30. doi: 10.1016/S0006-8993(02)03262-6.
11. Apostolova, L. G., and Cummings, J. L. (2008). Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dement. Geriatr. Cogn. Disord. 25, 115-126. doi: 10.1159/000112509.
12. Arendash, G. W., Gordon, M. N., Diamond, D. M., Austin, L. A., Hatcher, J. M., Jantzen, P., et al. (2001a). Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory. DNA Cell Biol. 20, 737-744. doi: 10.1089/10445490152717604.
13. Arendash, G. W., King, D. L., Gordon, M. N., Morgan, D., Hatcher, J. M., Hope, C. E., et al. (2001b). Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res. 891, 42-53. doi: 10.1016/S0006-8993(00)03186-3.
14. Arendash, G. W., Lewis, J., Leighty, R. E., Mcgowan, E., Cracchiolo, J. R., Hutton, M., et al. (2004). Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain. Brain Res. 1012, 29-41. doi: 10.1016/j.brainres.2004.02.081.
15. Arnett, P. A., Rao, S. M., Bernardin, L., Grafman, J., Yetkin, F. Z., and Lobeck, L. (1994). Relationship between frontal lobe lesions and Wisconsin Card Sorting Test performance in patients with multiple sclerosis. Neurology 44, 420-425. doi: 10.1212/WNL.44.3_Part_1.420.
16. Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., and Hyman, B. T. (1992). Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631-639. doi: 10.1212/WNL.42.3.631.
17. Arsenault, D., Julien, C., Tremblay, C., and Calon, F. (2011). DHA improves cognition and prevents dysfunction of entorhinal cortex neurons in 3xTg-AD mice. PLoS ONE 6:e17397. doi: 10.1371/journal.pone.0017397.
18. Arsland, D. (1995). Aggressive-behavior in dementia and its pharmacological treatment - a review. Nord. J. Psychiatry 49, 111-118. doi: 10.3109/08039489509011892.
19. Ashe, K. H., and Zahs, K. R. (2010). Probing the biology of Alzheimer's disease in mice. Neuron 66, 631-645. doi: 10.1016/j.neuron.2010.04.031.
20. Auld, D. S., Kornecook, T. J., Bastianetto, S., and Quirion, R. (2002). Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog. Neurobiol. 68, 209-245. doi: 10.1016/S0301-0082(02)00079-5.
21. Backman, L., Jones, S., Berger, A. K., Laukka, E. J., and Small, B. J. (2005). Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. Neuropsychology 19, 520-531. doi: 10.1037/0894-4105.19.4.520.
22. Backman, L., Small, B. J., and Fratiglioni, L. (2001). Stability of the preclinical episodic memory deficit in Alzheimer's disease. Brain 124, 96-102. doi: 10.1093/brain/124.1.96.
23. Baddeley, A., Logie, R., Bressi, S., Della Sala, S., and Spinnler, H. (1986). Dementia and working memory. Q. J. Exp. Psychol. A 38, 603-618. doi: 10.1080/14640748608401616.
24. Baddeley, A. D., Baddeley, H. A., Bucks, R. S., and Wilcock, G. K. (2001). Attentional control in Alzheimer's disease. Brain 124, 1492-1508. doi: 10.1093/brain/124.8.1492.
25. Baddeley, A. D., Bressi, S., Della Sala, S., Logie, R., and Spinnler, H. (1991). The decline of working memory in Alzheimer's disease. A longitudinal study. Brain 114(Pt 6), 2521-2542. doi: 10.1093/brain/114.6.2521.
26. Bari, A., Dalley, J. W., and Robbins, T. W. (2008). The application of the 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats. Nat. Protoc. 3, 759-767. doi: 10.1038/nprot.2008.41.
27. Barnes, C. A. (1979). Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. J. Comp. Physiol. Psychol. 93, 74-104. doi: 10.1037/h0077579.
28. Beach, T. G., Adler, C. H., Lue, L., Sue, L. I., Bachalakuri, J., Henry-Watson, J., et al. (2009). Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 117, 613-634. doi: 10.1007/s00401-009-0538-8.
29. Beck, L. H., Bransome, E. D. Jr., Mirsky, A. F., Rosvold, H. E., and Sarason, I. (1956). A continuous performance test of brain damage. J. Consult. Psychol. 20, 343-350. doi: 10.1037/h0043220.
30. Bedrosian, T. A., Herring, K. L., Weil, Z. M., and Nelson, R. J. (2011). Altered temporal patterns of anxiety in aged and amyloid precursor protein (APP) transgenic mice. Proc. Natl. Acad. Sci. USA. 108, 11686-11691. doi: 10.1073/pnas.1103098108.
31. Benedict, R. H. B., and Groninger, L. (1994). Preliminary standardization and validation of a multiple-form test for the assessment of visuospatial memory. Arch. Clin. Neuropsychol. 9, 109-110.
32. Benedict, R. H. B., Schretlen, D., Groninger, L., and Brandt, J. (1998). Hopkins verbal learning test revised: normative data and analysis of inter-form and test-retest reliability. Clin. Neuropsychol. 12, 43-55. doi: 10.1076/clin.12.1.43.1726.
33. Bennett, D. A., Schneider, J. A., Wilson, R. S., Bienias, J. L., and Arnold, S. E. (2004). Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch. Neurol. 61, 378-384. doi: 10.1001/archneur.61.3.378.
34. Benton, A. L. (1992). Benton Visual Retention Test, 5th Edn. San Antonio, TX: The Psychological Corporation.
35. Berg, L., Mckeel, D. W. Jr., Miller, J. P., Storandt, M., Rubin, E. H., Morris, J. C., et al. (1998). Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch. Neurol. 55, 326-335. doi: 10.1001/archneur.55.3.326.
36. Berlau, D. J., Kahle-Wrobleski, K., Head, E., Goodus, M., Kim, R., and Kawas, C. (2007). Dissociation of neuropathologic findings and cognition: case report of an apolipoprotein E epsilon2/epsilon2 genotype. Arch. Neurol. 64, 1193-1196. doi: 10.1001/archneur.64.8.1193.
37. Berman, K. F., Ostrem, J. L., Randolph, C., Gold, J., Goldberg, T. E., Coppola, R., et al. (1995). Physiological activation of a cortical network during performance of the Wisconsin Card Sorting Test: a positron emission tomography study. Neuropsychologia 33, 1027-1046. doi: 10.1016/0028-3932(95)00035-2.
38. Bernardo, A., Harrison, F. E., Mccord, M., Zhao, J., Bruchey, A., Davies, S. S., et al. (2009). Elimination of GD3 synthase improves memory and reduces amyloid-beta plaque load in transgenic mice. Neurobiol. Aging 30, 1777-1791. doi: 10.1016/j.neurobiolaging.2007.12.022.
39. Bernick, C., Cummings, J., Raman, R., Sun, X., and Aisen, P. (2012). Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch. Neurol. 69, 901-905. doi: 10.1001/archneurol.2011.3758.
40. Bierer, L. M., Hof, P. R., Purohit, D. P., Carlin, L., Schmeidler, J., Davis, K. L., et al. (1995). Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch. Neurol. 52, 81-88. doi: 10.1001/archneur.1995.00540250089017.
41. Billings, L. M., Oddo, S., Green, K. N., Mcgaugh, J. L., and Laferla, F. M. (2005). Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45, 675-688. doi: 10.1016/j.neuron.2005.01.040.
42. Birrell, J. M., and Brown, V. J. (2000). Medial frontal cortex mediates perceptual attentional set shifting in the rat. J. Neurosci. 20, 4320-4324. Available online at: http://www.jneurosci.org/content/20/11/4320.long.
43. Bissonette, G. B., Martins, G. J., Franz, T. M., Harper, E. S., Schoenbaum, G., and Powell, E. M. (2008). Double dissociation of the effects of medial and orbital prefrontal cortical lesions on attentional and affective shifts in mice. J. Neurosci. 28, 11124-11130. doi: 10.1523/JNEUROSCI.2820-08.2008.
44. Blennow, K., and Zetterberg, H. (2013). The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease. Med. Clin. North Am. 97, 369-376. doi: 10.1016/j.mcna.2012.12.012.
45. Blessed, G., Tomlinson, B. E., and Roth, M. (1968). The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br. J. Psychiatry 114, 797-811. doi: 10.1192/bjp.114.512.797.
46. Bliwise, D. L. (1994). What is sundowning? J. Am. Geriatr. Soc. 42, 1009-1011.
47. Blodgett, H. C., and Mccutchan, K. (1947). Place versus response learning in the simple T-maze. J. Exp. Psychol. 37, 412-422. doi: 10.1037/h0059305.
48. Bondi, M. W., Jak, A. J., Delano-Wood, L., Jacobson, M. W., Delis, D. C., and Salmon, D. P. (2008). Neuropsychological contributions to the early identification of Alzheimer's disease. Neuropsychol. Rev. 18, 73-90. doi: 10.1007/s11065-008-9054-1.
49. Bondi, M. W., Salmon, D. P., Galasko, D., Thomas, R. G., and Thal, L. J. (1999). Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease. Psychol. Aging 14, 295-303. doi: 10.1037/0882-7974.14.2.295.
50. Bondi, M. W., Salmon, D. P., Monsch, A. U., Galasko, D., Butters, N., Klauber, M. R., et al. (1995). Episodic memory changes are associated with the APOE-epsilon 4 allele in nondemented older adults. Neurology 45, 2203-2206. doi: 10.1212/WNL.45.12.2203.
51. Braak, H., and Del Tredici, K. (2011). The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol. 121, 171-181. doi: 10.1007/s00401-010-0789-4.
52. Braak, H., Thal, D. R., Ghebremedhin, E., and Del Tredici, K. (2011). Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960-969. doi: 10.1097/NEN.0b013e318232a379.
53. Brayne, C., Richardson, K., Matthews, F. E., Fleming, J., Hunter, S., Xuereb, J. H., et al. (2009). Neuropathological correlates of dementia in over-80-year-old brain donors from the population-based Cambridge city over-75s cohort (CC75C) study. J. Alzheimers Dis. 18, 645-658. doi: 10.3233/JAD-2009-1182.
54. Brigman, J. L., Bussey, T. J., Saksida, L. M., and Rothblat, L. A. (2005). Discrimination of multidimensional visual stimuli by mice: intra- and extradimensional shifts. Behav. Neurosci. 119, 839-842. doi: 10.1037/0735-7044.119.3.839.
55. Bruce-Keller, A. J., Gupta, S., Knight, A. G., Beckett, T. L., Mcmullen, J. M., Davis, P. R., et al. (2011). Cognitive impairment in humanized APPxPS1 mice is linked to Abeta (1-42) and NOX activation. Neurobiol. Dis. 44, 317-326. doi: 10.1016/j.nbd.2011.07.012.
56. Buccafusco, J. J., Terry, A. V. Jr., Webster, S. J., Martin, D., Hohnadel, E. J., Bouchard, K. A., et al. (2008). The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates. Psychopharmacology (Berl.) 199, 481-494. doi: 10.1007/s00213-007-0887-8.
57. Budson, A. E., and Price, B. H. (2005). Memory dysfunction. N. Engl. J. Med. 352, 692-699. doi: 10.1056/NEJMra041071.
58. Burns, A., Jacoby, R., and Levy, R. (1990a). Psychiatric phenomena in Alzheimer's disease. II: Disorders of perception. Br. J. Psychiatry 157, 76-81, 92-74.
59. Burns, A., Jacoby, R., and Levy, R. (1990b). Psychiatric phenomena in Alzheimer's disease. IV: Disorders of behaviour. Br. J. Psychiatry 157, 86-94. doi: 10.1192/bjp.157.1.86.
60. Bussey, T. J., Holmes, A., Lyon, L., Mar, A. C., Mcallister, K. A., Nithianantharajah, J., et al. (2012). New translational assays for preclinical modelling of cognition in schizophrenia: the touchscreen testing method for mice and rats. Neuropharmacology 62, 1191-1203. doi: 10.1016/j.neuropharm.2011.04.011.
61. Bussey, T. J., Muir, J. L., Everitt, B. J., and Robbins, T. W. (1997). Triple dissociation of anterior cingulate, posterior cingulate, and medial frontal cortices on visual discrimination tasks using a touchscreen testing procedure for the rat. Behav. Neurosci. 111, 920-936. doi: 10.1037/0735-7044.111.5.920.
62. Butter, C. M. (1969). Perseveration in extinction and in discrimination reversal tasks following selective frontal ablations in Macaca mulatta. Physiol. Behav. 4, 163-171. doi: 10.1016/0031-9384(69)90075-4.
63. Butters, M. A., Becker, J. T., Nebes, R. D., Zmuda, M. D., Mulsant, B. H., Pollock, B. G. 3rd., et al. (2000). Changes in cognitive functioning following treatment of late-life depression. Am. J. Psychiatry 157, 1949-1954. doi: 10.1176/appi.ajp.157.12.1949.
64. Butters, M. A., Young, J. B., Lopez, O., Aizenstein, H. J., Mulsant, B. H., Reynolds, C. F., et al. (2008). Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin. Neurosci. 10, 345-357.
65. Campion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., et al. (1999). Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am. J. Hum. Genet. 65, 664-670. doi: 10.1086/302553.
66. Cao, D., Lu, H., Lewis, T. L., and Li, L. (2007). Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J. Biol. Chem. 282, 36275-36282. doi: 10.1074/jbc.M703561200.
67. Carli, M., Robbins, T. W., Evenden, J. L., and Everitt, B. J. (1983). Effects of lesions to ascending noradrenergic neurones on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal. Behav. Brain Res. 9, 361-380. doi: 10.1016/0166-4328(83)90138-9.
68. Carpenter, C. R., Bassett, E. R., Fischer, G. M., Shirshekan, J., Galvin, J. E., and Morris, J. C. (2011). Four sensitive screening tools to detect cognitive dysfunction in geriatric emergency department patients: brief Alzheimer's Screen, Short Blessed Test, Ottawa 3DY, and the caregiver-completed AD8. Acad. Emerg. Med. 18, 374-384. doi: 10.1111/j.1553-2712.2011.01040.x.
69. Carroll, J. C., Rosario, E. R., Chang, L., Stanczyk, F. Z., Oddo, S., Laferla, F. M., et al. (2007). Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J. Neurosci. 27, 13357-13365. doi: 10.1523/JNEUROSCI.2718-07.2007.
70. Chapman, P. F., White, G. L., Jones, M. W., Cooper-Blacketer, D., Marshall, V. J., Irizarry, M., et al. (1999). Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2, 271-276. doi: 10.1038/6374.
71. Charlson, M., and Peterson, J. C. (2002). Medical comorbidity and late life depression: what is known and what are the unmet needs? Biol. Psychiatry 52, 226-235. doi: 10.1016/S0006-3223(02)01422-1.
72. Chartier-Harlin, M. C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., et al. (1991). Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 353, 844-846. doi: 10.1038/353844a0.
73. Chatfield, M., Matthews, F. E., Brayne, C., Medical Research Council Cognitive, F., and Ageing, S. (2007). Using the Mini-Mental State Examination for tracking cognition in the older population based on longitudinal data. J. Am. Geriatr. Soc. 55, 1066-1071. doi: 10.1111/j.1532-5415.2007.01216.x.
74. Chen, G., Chen, K. S., Knox, J., Inglis, J., Bernard, A., Martin, S. J., et al. (2000). A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408, 975-979. doi: 10.1038/35046031.
75. Chen, P., Ganguli, M., Mulsant, B. H., and Dekosky, S. T. (1999). The temporal relationship between depressive symptoms and dementia: a community-based prospective study. Arch. Gen. Psychiatry 56, 261-266. doi: 10.1001/archpsyc.56.3.261.
76. Cheng, D., Low, J. K., Logge, W., Garner, B., and Karl, T. (2013). Novel behavioural characteristics of female APP/PS1DeltaE9 double transgenic mice. Behav. Brain Res. 260, 111-118. doi: 10.1016/j.bbr.2013.11.046.
77. Cheng, I. H., Scearce-Levie, K., Legleiter, J., Palop, J. J., Gerstein, H., Bien-Ly, N., et al. (2007). Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 282, 23818-23828. doi: 10.1074/jbc.M701078200.
78. Chishti, M. A., Yang, D. S., Janus, C., Phinney, A. L., Horne, P., Pearson, J., et al. (2001). Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276, 21562-21570. doi: 10.1074/jbc.M100710200.
79. Chudasama, Y. (2011). Animal models of prefrontal-executive function. Behav. Neurosci. 125, 327-343. doi: 10.1037/a0023766.
80. Chung, J. A., and Cummings, J. L. (2000). Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment. Neurol. Clin. 18, 829-846. doi: 10.1016/S0733-8619(05)70228-0.
81. Cisse, M., Sanchez, P. E., Kim, D. H., Ho, K., Yu, G. Q., and Mucke, L. (2011). Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. J. Neurosci. 31, 10427-10431. doi: 10.1523/JNEUROSCI.1459-11.2011.
82. Clayton, N. S., and Dickinson, A. (1998). Episodic-like memory during cache recovery by scrub jays. Nature 395, 272-274. doi: 10.1038/26216.
83. Clayton, N. S., Griffiths, D. P., Emery, N. J., and Dickinson, A. (2001). Elements of episodic-like memory in animals. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356, 1483-1491. doi: 10.1098/rstb.2001.0947.
84. Clinton, L. K., Billings, L. M., Green, K. N., Caccamo, A., Ngo, J., Oddo, S., et al. (2007). Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. Neurobiol. Dis. 28, 76-82. doi: 10.1016/j.nbd.2007.06.013.
85. Collie, A., and Maruff, P. (2000). The neuropsychology of preclinical Alzheimer's disease and mild cognitive impairment. Neurosci. Biobehav. Rev. 24, 365-374. doi: 10.1016/S0149-7634(00)00012-9.
86. Connor, D. J., and Sabbagh, M. N. (2008). Administration and scoring variance on the ADAS-Cog. J. Alzheimers Dis. 15, 461-464.
87. Corcoran, K. A., Lu, Y., Turner, R. S., and Maren, S. (2002). Overexpression of hAPPswe impairs rewarded alternation and contextual fear conditioning in a transgenic mouse model of Alzheimer's disease. Learn. Mem. 9, 243-252. doi: 10.1101/lm.51002.
88. Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y., Karlo, J. C., Zinn, A. E., et al. (2012). ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335, 1503-1506. doi: 10.1126/science.1217697.
89. Crusio, W. E., Schwegler, H., and Brust, I. (1993). Covariations between hippocampal mossy fibres and working and reference memory in spatial and non-spatial radial maze tasks in mice. Eur. J. Neurosci. 5, 1413-1420. doi: 10.1111/j.1460-9568.1993.tb00927.x.
90. Crystal, H. A., Dickson, D. W., Sliwinski, M. J., Lipton, R. B., Grober, E., Marks-Nelson, H., et al. (1993). Pathological markers associated with normal aging and dementia in the elderly. Ann. Neurol. 34, 566-573. doi: 10.1002/ana.410340410.
91. Cummings, B. J., Pike, C. J., Shankle, R., and Cotman, C. W. (1996). Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol. Aging 17, 921-933. doi: 10.1016/S0197-4580(96)00170-4.
92. Cummings, J. L. (2000). Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis. Neurobiol. Aging 21, 845-861. doi: 10.1016/S0197-4580(00)00183-4.
93. Curzon, P., Rustay, N. R., and Browman, K. E. (2009). "Cued and Contextual Fear Conditioning for Rodents," in Methods of Behavior Analysis in Neuroscience, Chapter 2, 2nd Edn. ed J. J. Buccafusco (Boca Raton, FL: CRC Press), 26-49.
94. Daffner, K. R., Scinto, L. F., Weintraub, S., Guinessey, J. E., and Mesulam, M. M. (1992). Diminished curiosity in patients with probable Alzheimer's disease as measured by exploratory eye movements. Neurology 42, 320-328. doi: 10.1212/WNL.42.2.320.
95. Daumas, S., Sandin, J., Chen, K. S., Kobayashi, D., Tulloch, J., Martin, S. J., et al. (2008). Faster forgetting contributes to impaired spatial memory in the PDAPP mouse: deficit in memory retrieval associated with increased sensitivity to interference? Learn. Mem. 15, 625-632. doi: 10.1101/lm.990208.
96. Davis, K. E., Eacott, M. J., Easton, A., and Gigg, J. (2013a). Episodic-like memory is sensitive to both Alzheimer's-like pathological accumulation and normal ageing processes in mice. Behav. Brain Res. 254, 73-82. doi: 10.1016/j.bbr.2013.03.009.
97. Davis, K. E., Easton, A., Eacott, M. J., and Gigg, J. (2013b). Episodic-like memory for what-where-which occasion is selectively impaired in the 3xTgAD mouse model of Alzheimer's disease. J. Alzheimers Dis. 33, 681-698. doi: 10.3233/JAD-2012-121543.
98. Davis, P. C., Gearing, M., Gray, L., Mirra, S. S., Morris, J. C., Edland, S. D., et al. (1995). The CERAD experience, Part VIII: neuroimaging-neuropathology correlates of temporal lobe changes in Alzheimer's disease. Neurology 45, 178-179. doi: 10.1212/WNL.45.1.178.
99. De Bruin, N. M., Fransen, F., Duytschaever, H., Grantham, C., and Megens, A. A. (2006). Attentional performance of (C57BL/6Jx129Sv) F2 mice in the five-choice serial reaction time task. Physiol. Behav. 89, 692-703. doi: 10.1016/j.physbeh.2006.08.009.
100. Delis, D. C., Kaplan, E., Kramer, J. H., and Ober, B. A. (2000). California Verbal Learning Test - Second Edition (CVLT - II) Manual. San Antonio, TX: Psychological Corperation.
101. Devanand, D. P., Sano, M., Tang, M. X., Taylor, S., Gurland, B. J., Wilder, D., et al. (1996). Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch. Gen. Psychiatry 53, 175-182. doi: 10.1001/archpsyc.1996.01830020093011.
102. Devi, L., and Ohno, M. (2010). Genetic reductions of beta-site amyloid precursor protein-cleaving enzyme 1 and amyloid-beta ameliorate impairment of conditioned taste aversion memory in 5XFAD Alzheimer's disease model mice. Eur. J. Neurosci. 31, 110-118. doi: 10.1111/j.1460-9568.2009.07031.x.
103. Devi, L., and Ohno, M. (2012). Mitochondrial dysfunction and accumulation of the beta-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice. Neurobiol. Dis. 45, 417-424. doi: 10.1016/j.nbd.2011.09.001.
104. Diamond, D. M., Park, C. R., Heman, K. L., and Rose, G. M. (1999). Exposing rats to a predator impairs spatial working memory in the radial arm water maze. Hippocampus 9, 542-552.
105. Dickson, D. W., Crystal, H. A., Bevona, C., Honer, W., Vincent, I., and Davies, P. (1995). Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol. Aging 16, 285-298. discussion: 298-304. doi: 10.1016/0197-4580(95)00013-5.
106. Dineley, K. T., Xia, X., Bui, D., Sweatt, J. D., and Zheng, H. (2002). Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J. Biol. Chem. 277, 22768-22780. doi: 10.1074/jbc.M200164200.
107. Ding, Y., Qiao, A., Wang, Z., Goodwin, J. S., Lee, E. S., Block, M. L., et al. (2008). Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. J. Neurosci. 28, 11622-11634. doi: 10.1523/JNEUROSCI.3153-08.2008.
108. Diniz, B. S., Butters, M. A., Albert, S. M., Dew, M. A., and Reynolds, C. F. 3rd. (2013). Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies. Br. J. Psychiatry 202, 329-335. doi: 10.1192/bjp.bp.112.118307.
109. Dodart, J. C., Bales, K. R., Gannon, K. S., Greene, S. J., Demattos, R. B., Mathis, C., et al. (2002). Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5, 452-457. doi: 10.1038/nn842.
110. Dodart, J. C., Meziane, H., Mathis, C., Bales, K. R., Paul, S. M., and Ungerer, A. (1999). Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Behav. Neurosci. 113, 982-990. doi: 10.1037/0735-7044.113.5.982.
111. Dong, H., Csernansky, C. A., Martin, M. V., Bertchume, A., Vallera, D., and Csernansky, J. G. (2005). Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease. Psychopharmacology (Berl.) 181, 145-152. doi: 10.1007/s00213-005-2230-6.
112. Drewe, E. A. (1974). The effect of type and area of brain lesion on Wisconsin card sorting test performance. Cortex 10, 159-170. doi: 10.1016/S0010-9452(74)80006-7.
113. Du, H., Guo, L., Zhang, W., Rydzewska, M., and Yan, S. (2011). Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model. Neurobiol. Aging 32, 398-406. doi: 10.1016/j.neurobiolaging.2009.03.003.
114. Dudchenko, P. A. (2004). An overview of the tasks used to test working memory in rodents. Neurosci. Biobehav. Rev. 28, 699-709. doi: 10.1016/j.neubiorev.2004.09.002.
115. Dumont, M., Strazielle, C., Staufenbiel, M., and Lalonde, R. (2004). Spatial learning and exploration of environmental stimuli in 24-month-old female APP23 transgenic mice with the Swedish mutation. Brain Res. 1024, 113-121. doi: 10.1016/j.brainres.2004.07.052.
116. Dunnett, S. B. (1993). The role and repair of forebrain cholinergic systems in short-term memory. Studies using the delayed matching-to-position task in rats. Adv. Neurol. 59, 53-65.
117. Duyckaerts, C., Bennecib, M., Grignon, Y., Uchihara, T., He, Y., Piette, F., et al. (1997). Modeling the relation between neurofibrillary tangles and intellectual status. Neurobiol. Aging 18, 267-273. doi: 10.1016/S0197-4580(97)80306-5.
118. Duyckaerts, C., Colle, M. A., Dessi, F., Piette, F., and Hauw, J. J. (1998). Progression of Alzheimer histopathological changes. Acta Neurol. Belg. 98, 180-185.
119. Duyckaerts, C., Delaere, P., Hauw, J. J., Abbamondi-Pinto, A. L., Sorbi, S., Allen, I., et al. (1990). Rating of the lesions in senile dementia of the Alzheimer type: concordance between laboratories. A European multicenter study under the auspices of EURAGE. J. Neurol. Sci. 97, 295-323. doi: 10.1016/0022-510X(90)90226-D.
120. Elder, G. A., Gama Sosa, M. A., and De Gasperi, R. (2010). Transgenic mouse models of Alzheimer's disease. Mt. Sinai J. Med. 77, 69-81. doi: 10.1002/msj.20159.
121. Emilien, G., Durlach, C., Minaker, K. L., Winblad, B., Gauthier, S., and Maloteaux, J.-M. (2004). Alzheimer Disease: Neuropsychology and Pharmacology. Basel: Birkhauser Verlag.
122. Ennaceur, A., and Delacour, J. (1988). A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav. Brain Res. 31, 47-59. doi: 10.1016/0166-4328(88)90157-X.
123. Epis, R., Gardoni, F., Marcello, E., Genazzani, A., Canonico, P. L., and Di Luca, M. (2010). Searching for new animal models of Alzheimer's disease. Eur. J. Pharmacol. 626, 57-63. doi: 10.1016/j.ejphar.2009.10.020.
124. Eriksen, J. L., and Janus, C. G. (2007). Plaques, tangles, and memory loss in mouse models of neurodegeneration. Behav. Genet. 37, 79-100. doi: 10.1007/s10519-006-9118-z.
125. Escribano, L., Simon, A. M., Perez-Mediavilla, A., Salazar-Colocho, P., Del Rio, J., and Frechilla, D. (2009). Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem. Biophys. Res. Commun. 379, 406-410. doi: 10.1016/j.bbrc.2008.12.071.
126. Espana, J., Gimenez-Llort, L., Valero, J., Minano, A., Rabano, A., Rodriguez-Alvarez, J., et al. (2010). Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. Biol. Psychiatry 67, 513-521. doi: 10.1016/j.biopsych.2009.06.015.
127. Fang, F., Chen, X., Huang, T., Lue, L. F., Luddy, J. S., and Yan, S. S. (2012). Multi-faced neuroprotective effects of Ginsenoside Rg1 in an Alzheimer mouse model. Biochim. Biophys. Acta 1822, 286-292. doi: 10.1016/j.bbadis.2011.10.004.
128. Fanselow, M. S. (1980). Conditioned and unconditional components of post-shock freezing. Pavlov. J. Biol. Sci. 15, 177-182.
129. Filali, M., Lalonde, R., and Rivest, S. (2009). Cognitive and non-cognitive behaviors in an APPswe/PS1 bigenic model of Alzheimer's disease. Genes Brain Behav. 8, 143-148. doi: 10.1111/j.1601-183X.2008.00453.x.
130. Filali, M., Lalonde, R., Theriault, P., Julien, C., Calon, F., and Planel, E. (2012). Cognitive and non-cognitive behaviors in the triple transgenic mouse model of Alzheimer's disease expressing mutated APP, PS1, and Mapt (3xTg-AD). Behav. Brain Res. 234, 334-342. doi: 10.1016/j.bbr.2012.07.004.
131. Flicker, C., Bartus, R. T., Crook, T. H., and Ferris, S. H. (1984). Effects of aging and dementia upon recent visuospatial memory. Neurobiol. Aging 5, 275-283. doi: 10.1016/0197-4580(84)90003-4.
132. Flint, J., and Shifman, S. (2008). Animal models of psychiatric disease. Curr. Opin. Genet. Dev. 18, 235-240. doi: 10.1016/j.gde.2008.07.002.
133. Flood, D. G., Reaume, A. G., Dorfman, K. S., Lin, Y. G., Lang, D. M., Trusko, S. P., et al. (2002). FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction. Neurobiol. Aging 23, 335-348. doi: 10.1016/S0197-4580(01)00330-X.
134. Folstein, M. F., Folstein, S. E., and Mchugh, P. R. (1975). "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189-198. doi: 10.1016/0022-3956(75)90026-6.
135. Fuld, P. (1978). Psychological Testing in the Differential Diagnosis of the Dementias. New York, NY: Raven Press.
136. Galvan, V., Gorostiza, O. F., Banwait, S., Ataie, M., Logvinova, A. V., Sitaraman, S., et al. (2006). Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc. Natl. Acad. Sci. U.S.A. 103, 7130-7135. doi: 10.1073/pnas.0509695103.
137. Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., et al. (1995). Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373, 523-527. doi: 10.1038/373523a0.
138. Giannakopoulos, P., Kovari, E., Gold, G., Von Gunten, A., Hof, P. R., and Bouras, C. (2009). Pathological substrates of cognitive decline in Alzheimer's disease. Front. Neurol. Neurosci. 24, 20-29. doi: 10.1159/000197881.
139. Gibson, A. P., Bettinger, T. L., Patel, N. C., and Crismon, M. L. (2006). Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann. Pharmacother. 40, 1134-1142. doi: 10.1345/aph.1G582.
140. Gil-Bea, F. J., Aisa, B., Schliebs, R., and Ramirez, M. J. (2007). Increase of locomotor activity underlying the behavioral disinhibition in tg2576 mice. Behav. Neurosci. 121, 340-344. doi: 10.1037/0735-7044.121.2.340.
141. Gimenez-Llort, L., Blazquez, G., Canete, T., Johansson, B., Oddo, S., Tobena, A., et al. (2007). Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. Neurosci. Biobehav. Rev. 31, 125-147. doi: 10.1016/j.neubiorev.2006.07.007.
142. Glickman, S. E., and Jensen, G. D. (1961). The effects of hunger and thirst on Y-maze exploration. J. Comp. Physiol. Psychol. 54, 83-85. doi: 10.1037/h0049301.
143. Gold, G., Bouras, C., Kovari, E., Canuto, A., Glaria, B. G., Malky, A., et al. (2000). Clinical validity of Braak neuropathological staging in the oldest-old. Acta Neuropathol. 99, 579-582. discussion: 583-574. doi: 10.1007/s004010051163.
144. Gordon, M. N., King, D. L., Diamond, D. M., Jantzen, P. T., Boyett, K. V., Hope, C. E., et al. (2001). Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol. Aging 22, 377-385. doi: 10.1016/S0197-4580(00)00249-9.
145. Gortz, N., Lewejohann, L., Tomm, M., Ambree, O., Keyvani, K., Paulus, W., et al. (2008). Effects of environmental enrichment on exploration, anxiety, and memory in female TgCRND8 Alzheimer mice. Behav. Brain Res. 191, 43-48. doi: 10.1016/j.bbr.2008.03.006.
146. Graves, L., Pack, A., and Abel, T. (2001). Sleep and memory: a molecular perspective. Trends Neurosci. 24, 237-243. doi: 10.1016/S0166-2236(00)01744-6.
147. Griffiths, D. P., and Clayton, N. S. (2001). Testing episodic memory in animals: a new approach. Physiol. Behav. 73, 755-762. doi: 10.1016/S0031-9384(01)00532-7.
148. Grober, E., Dickson, D., Sliwinski, M. J., Buschke, H., Katz, M., Crystal, H., et al. (1999). Memory and mental status correlates of modified Braak staging. Neurobiol. Aging 20, 573-579. doi: 10.1016/S0197-4580(99)00063-9.
149. Guillozet, A. L., Weintraub, S., Mash, D. C., and Mesulam, M. M. (2003). Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch. Neurol. 60, 729-736. doi: 10.1001/archneur.60.5.729.
150. Halagappa, V. K., Guo, Z., Pearson, M., Matsuoka, Y., Cutler, R. G., Laferla, F. M., et al. (2007). Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 26, 212-220. doi: 10.1016/j.nbd.2006.12.019.
151. Hall, A. M., and Roberson, E. D. (2012). Mouse models of Alzheimer's disease. Brain Res. Bull. 88, 3-12. doi: 10.1016/j.brainresbull.2011.11.017.
152. Hanna, A., Horne, P., Yager, D., Eckman, C., Eckman, E., and Janus, C. (2009). Amyloid beta and impairment in multiple memory systems in older transgenic APP TgCRND8 mice. Genes Brain Behav. 8, 676-684. doi: 10.1111/j.1601-183X.2009.00510.x.
153. Hanna, A., Iremonger, K., Das, P., Dickson, D., Golde, T., and Janus, C. (2012). Age-related increase in amyloid plaque burden is associated with impairment in conditioned fear memory in CRND8 mouse model of amyloidosis. Alzheimers Res. Ther. 4, 21. doi: 10.1186/alzrt124.
154. Harper, D. G., Stopa, E. G., Mckee, A. C., Satlin, A., Fish, D., and Volicer, L. (2004). Dementia severity and Lewy bodies affect circadian rhythms in Alzheimer disease. Neurobiol. Aging 25, 771-781. doi: 10.1016/j.neurobiolaging.2003.04.009.
155. Harris, J. A., Devidze, N., Halabisky, B., Lo, I., Thwin, M. T., Yu, G. Q., et al. (2010). Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. J. Neurosci. 30, 372-381. doi: 10.1523/JNEUROSCI.5341-09.2010.
156. Hartman, R. E., Izumi, Y., Bales, K. R., Paul, S. M., Wozniak, D. F., and Holtzman, D. M. (2005). Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J. Neurosci. 25, 6213-6220. doi: 10.1523/JNEUROSCI.0664-05.2005.
157. Heneka, M. T., Ramanathan, M., Jacobs, A. H., Dumitrescu-Ozimek, L., Bilkei-Gorzo, A., Debeir, T., et al. (2006). Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J. Neurosci. 26, 1343-1354. doi: 10.1523/JNEUROSCI.4236-05.2006.
158. Hochgrafe, K., Sydow, A., and Mandelkow, E. M. (2013). Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology. FEBS J. 280, 4371-4381. doi: 10.1111/febs.12250.
159. Hodges, J. R., and Patterson, K. (1995). Is semantic memory consistently impaired early in the course of Alzheimer's disease? Neuroanatomical and diagnostic implications. Neuropsychologia 33, 441-459. doi: 10.1016/0028-3932(94)00127-B.
160. Hodges, J. R., Salmon, D. P., and Butters, N. (1992). Semantic memory impairment in Alzheimer's disease: failure of access or degraded knowledge? Neuropsychologia 30, 301-314. doi: 10.1016/0028-3932(92)90104-T.
161. Hof, P. R., Vogt, B. A., Bouras, C., and Morrison, J. H. (1997). Atypical form of Alzheimer's disease with prominent posterior cortical atrophy: a review of lesion distribution and circuit disconnection in cortical visual pathways. Vision Res. 37, 3609-3625. doi: 10.1016/S0042-6989(96)00240-4.
162. Holcomb, L., Gordon, M. N., Mcgowan, E., Yu, X., Benkovic, S., Jantzen, P., et al. (1998). Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4, 97-100. doi: 10.1038/nm0198-097.
163. Holcomb, L. A., Gordon, M. N., Jantzen, P., Hsiao, K., Duff, K., and Morgan, D. (1999). Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav. Genet. 29, 177-185. doi: 10.1023/A:1021691918517.
164. Holtzer, R., Irizarry, M. C., Sanders, J., Hyman, B. T., Wegesin, D. J., Riba, A., et al. (2006). Relation of quantitative indexes of concurrent alpha-synuclein abnormalities to clinical outcome in autopsy-proven Alzheimer disease. Arch. Neurol. 63, 226-230. doi: 10.1001/archneur.63.2.226.
165. Hope, T., Keene, J., Gedling, K., Fairburn, C. G., and Jacoby, R. (1998). Predictors of institutionalization for people with dementia living at home with a carer. Int. J. Geriatr. Psychiatry 13, 682-690.
166. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., et al. (1996). Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102. doi: 10.1126/science.274.5284.99.
167. Huang, S. M., Mouri, A., Kokubo, H., Nakajima, R., Suemoto, T., Higuchi, M., et al. (2006). Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J. Biol. Chem. 281, 17941-17951. doi: 10.1074/jbc.M601372200.
168. Huff, F. J., Becker, J. T., Belle, S. H., Nebes, R. D., Holland, A. L., and Boller, F. (1987). Cognitive deficits and clinical diagnosis of Alzheimer's disease. Neurology 37, 1119-1124. doi: 10.1212/WNL.37.7.1119.
169. Huitron-Resendiz, S., Sanchez-Alavez, M., and Criado, J. R. (2005). Sleep-wake states in transgenic mouse models overexpressing the human beta-amyloid precursor protein. Am. J. Alzheimers Dis. Other Demen. 20, 87-90. doi: 10.1177/153331750502000204.
170. Huitron-Resendiz, S., Sanchez-Alavez, M., Gallegos, R., Berg, G., Crawford, E., Giacchino, J. L., et al. (2002). Age-independent and age-related deficits in visuospatial learning, sleep-wake states, thermoregulation and motor activity in PDAPP mice. Brain Res. 928, 126-137. doi: 10.1016/S0006-8993(01)03373-X.
171. Humby, T., Laird, F. M., Davies, W., and Wilkinson, L. S. (1999). Visuospatial attentional functioning in mice: interactions between cholinergic manipulations and genotype. Eur. J. Neurosci. 11, 2813-2823. doi: 10.1046/j.1460-9568.1999.00701.x.
172. Hyde, L. A., Kazdoba, T. M., Grilli, M., Lozza, G., Brusa, R., Zhang, Q., et al. (2005). Age-progressing cognitive impairments and neuropathology in transgenic CRND8 mice. Behav. Brain Res. 160, 344-355. doi: 10.1016/j.bbr.2004.12.017.
173. Hyde, L. A., Sherman, G. F., and Denenberg, V. H. (2000). Non-spatial water radial-arm maze learning in mice. Brain Res. 863, 151-159. doi: 10.1016/S0006-8993(00)02113-2.
174. Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., et al. (2012). National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 8, 1-13. doi: 10.1016/j.jalz.2011.10.007.
175. Hyman, B. T., and Trojanowski, J. Q. (1997). Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J. Neuropathol. Exp. Neurol. 56, 1095-1097. doi: 10.1097/00005072-199710000-00002.
176. Izquierdo, A., and Jentsch, J. D. (2012). Reversal learning as a measure of impulsive and compulsive behavior in addictions. Psychopharmacology (Berl.) 219, 607-620. doi: 10.1007/s00213-011-2579-7.
177. Jacobson, M. W., Delis, D. C., Bondi, M. W., and Salmon, D. P. (2002). Do neuropsychological tests detect preclinical Alzheimer's disease: individual-test versus cognitive-discrepancy score analyses. Neuropsychology 16, 132-139. doi: 10.1037/0894-4105.16.2.132.
178. Jacqmin-Gadda, H., Fabrigoule, C., Commenges, D., and Dartigues, J. F. (1997). A 5-year longitudinal study of the Mini-Mental State Examination in normal aging. Am. J. Epidemiol. 145, 498-506. doi: 10.1093/oxfordjournals.aje.a009137.
179. Jankowsky, J. L., Slunt, H. H., Ratovitski, T., Jenkins, N. A., Copeland, N. G., and Borchelt, D. R. (2001). Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 17, 157-165. doi: 10.1016/S1389-0344(01)00067-3.
180. Janus, C. (2004). Search strategies used by APP transgenic mice during navigation in the Morris water maze. Learn. Mem. 11, 337-346. doi: 10.1101/lm.70104.
181. Janus, C., Pearson, J., Mclaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., et al. (2000). A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982. doi: 10.1038/35050110.
182. Janus, C., and Westaway, D. (2001). Transgenic mouse models of Alzheimer's disease. Physiol. Behav. 73, 873-886. doi: 10.1016/S0031-9384(01)00524-8.
183. Jicha, G. A., Abner, E. L., Schmitt, F. A., Kryscio, R. J., Riley, K. P., Cooper, G. E., et al. (2012). Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiol. Aging 33, 622.e621-622.e616. doi: 10.1016/j.neurobiolaging.2011.02.018.
184. Jolly, D. C., Richards, J. B., and Seiden, L. S. (1999). Serotonergic mediation of DRL 72s behavior: receptor subtype involvement in a behavioral screen for antidepressant drugs. Biol. Psychiatry 45, 1151-1162. doi: 10.1016/S0006-3223(98)00014-6.
185. Kaplan, E. F., Goodglass, H., and Weintraub, S. (1978). The Boston Naming Test. Philadelphia, PA: Lea & Febiger.
186. Karl, T., Bhatia, S., Cheng, D., Kim, W. S., and Garner, B. (2012). Cognitive phenotyping of amyloid precursor protein transgenic J20 mice. Behav. Brain Res. 228, 392-397. doi: 10.1016/j.bbr.2011.12.021.
187. Karran, E., Mercken, M., and De Strooper, B. (2011). The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10, 698-712. doi: 10.1038/nrd3505.
188. Katzman, R., Brown, T., Fuld, P., Peck, A., Schechter, R., and Schimmel, H. (1983). Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am. J. Psychiatry 140, 734-739.
189. Kelly, P. H., Bondolfi, L., Hunziker, D., Schlecht, H. P., Carver, K., Maguire, E., et al. (2003). Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol. Aging 24, 365-378. doi: 10.1016/S0197-4580(02)00098-2.
190. King, D. L., and Arendash, G. W. (2002). Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiol. Behav. 75, 627-642. doi: 10.1016/S0031-9384(02)00639-X.
191. King, D. L., Arendash, G. W., Crawford, F., Sterk, T., Menendez, J., and Mullan, M. J. (1999). Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behav. Brain Res. 103, 145-162. doi: 10.1016/S0166-4328(99)00037-6.
192. Klingner, M., Apelt, J., Kumar, A., Sorger, D., Sabri, O., Steinbach, J., et al. (2003). Alterations in cholinergic and non-cholinergic neurotransmitter receptor densities in transgenic Tg2576 mouse brain with beta-amyloid plaque pathology. Int. J. Dev. Neurosci. 21, 357-369. doi: 10.1016/j.ijdevneu.2003.08.001.
193. Knafo, S., Venero, C., Merino-Serrais, P., Fernaud-Espinosa, I., Gonzalez-Soriano, J., Ferrer, I., et al. (2009). Morphological alterations to neurons of the amygdala and impaired fear conditioning in a transgenic mouse model of Alzheimer's disease. J. Pathol. 219, 41-51. doi: 10.1002/path.2565.
194. Knopman, D. S., and Ryberg, S. (1989). A verbal memory test with high predictive accuracy for dementia of the Alzheimer type. Arch. Neurol. 46, 141-145. doi: 10.1001/archneur.1989.00520380041011.
195. Kobayashi, D. T., and Chen, K. S. (2005). Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Genes Brain Behav. 4, 173-196. doi: 10.1111/j.1601-183X.2005.00124.x.
196. Koepsell, T. D., Kurland, B. F., Harel, O., Johnson, E. A., Zhou, X. H., and Kukull, W. A. (2008). Education, cognitive function, and severity of neuropathology in Alzheimer disease. Neurology 70, 1732-1739. doi: 10.1212/01.wnl.0000284603.85621.aa.
197. Kraybill, M. L., Larson, E. B., Tsuang, D. W., Teri, L., Mccormick, W. C., Bowen, J. D., et al. (2005). Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 64, 2069-2073. doi: 10.1212/01.WNL.0000165987.89198.65.
198. Kryscio, R. J., Schmitt, F. A., Salazar, J. C., Mendiondo, M. S., and Markesbery, W. R. (2006). Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology 66, 828-832. doi: 10.1212/01.wnl.0000203264.71880.45.
199. Lalonde, R., Dumont, M., Staufenbiel, M., Sturchler-Pierrat, C., and Strazielle, C. (2002). Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation. Brain Res. 956, 36-44. doi: 10.1016/S0006-8993(02)03476-5.
200. Lalonde, R., Fukuchi, K., and Strazielle, C. (2012). Neurologic and motor dysfunctions in APP transgenic mice. Rev. Neurosci. 23, 363-379. doi: 10.1515/revneuro-2012-0041.
201. Lalonde, R., Kim, H. D., and Fukuchi, K. (2004). Exploratory activity, anxiety, and motor coordination in bigenic APPswe + PS1/DeltaE9 mice. Neurosci. Lett. 369, 156-161. doi: 10.1016/j.neulet.2004.07.069.
202. Lalonde, R., Kim, H. D., Maxwell, J. A., and Fukuchi, K. (2005). Exploratory activity and spatial learning in 12-month-old APP(695) SWE/co+PS1/DeltaE9 mice with amyloid plaques. Neurosci. Lett. 390, 87-92. doi: 10.1016/j.neulet.2005.08.028.
203. Lalonde, R., Lewis, T. L., Strazielle, C., Kim, H., and Fukuchi, K. (2003). Transgenic mice expressing the betaAPP695SWE mutation: effects on exploratory activity, anxiety, and motor coordination. Brain Res. 977, 38-45. doi: 10.1016/S0006-8993(03)02694-5.
204. Lambon Ralph, M. A., Patterson, K., Graham, N., Dawson, K., and Hodges, J. R. (2003). Homogeneity and heterogeneity in mild cognitive impairment and Alzheimer's disease: a cross-sectional and longitudinal study of 55 cases. Brain 126, 2350-2362. doi: 10.1093/brain/awg236.
205. Lambourne, S. L., Humby, T., Isles, A. R., Emson, P. C., Spillantini, M. G., and Wilkinson, L. S. (2007). Impairments in impulse control in mice transgenic for the human FTDP-17 tauV337M mutation are exacerbated by age. Hum. Mol. Genet. 16, 1708-1719. doi: 10.1093/hmg/ddm119.
206. Lange, K. L., Bondi, M. W., Salmon, D. P., Galasko, D., Delis, D. C., Thomas, R. G., et al. (2002). Decline in verbal memory during preclinical Alzheimer's disease: examination of the effect of APOE genotype. J. Int. Neuropsychol. Soc. 8, 943-955. doi: 10.1017/S1355617702870096.
207. Larrieu, S., Letenneur, L., Orgogozo, J. M., Fabrigoule, C., Amieva, H., Le Carret, N., et al. (2002). Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 59, 1594-1599. doi: 10.1212/01.WNL.0000034176.07159.F8.
208. Lassalle, J. M., Halley, H., Daumas, S., Verret, L., and Frances, B. (2008). Effects of the genetic background on cognitive performances of TG2576 mice. Behav. Brain Res. 191, 104-110. doi: 10.1016/j.bbr.2008.03.017.
209. Lenoir, H., Dufouil, C., Auriacombe, S., Lacombe, J. M., Dartigues, J. F., Ritchie, K., et al. (2011). Depression history, depressive symptoms, and incident dementia: the 3C Study. J. Alzheimers Dis. 26, 27-38. doi: 10.3233/JAD-2011-101614.
210. Locascio, J. J., Growdon, J. H., and Corkin, S. (1995). Cognitive test performance in detecting, staging, and tracking Alzheimer's disease. Arch. Neurol. 52, 1087-1099. doi: 10.1001/archneur.1995.00540350081020.
211. Lovasic, L., Bauschke, H., and Janus, C. (2005). Working memory impairment in a transgenic amyloid precursor protein TgCRND8 mouse model of Alzheimer's disease. Genes Brain Behav. 4, 197-208. doi: 10.1111/j.1601-183X.2004.00104.x.
212. Lustbader, J. W., Cirilli, M., Lin, C., Xu, H. W., Takuma, K., Wang, N., et al. (2004). ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304, 448-452. doi: 10.1126/science.1091230.
213. Luth, H. J., Apelt, J., Ihunwo, A. O., Arendt, T., and Schliebs, R. (2003). Degeneration of beta-amyloid-associated cholinergic structures in transgenic APP SW mice. Brain Res. 977, 16-22. doi: 10.1016/S0006-8993(03)02658-1.
214. Ma, T., Du, X., Pick, J. E., Sui, G., Brownlee, M., and Klann, E. (2012). Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice. J. Neurosci. 32, 13701-13708. doi: 10.1523/JNEUROSCI.2107-12.2012.
215. Marchese, M., Cowan, D., Head, E., Ma, D., Karimi, K., Ashthorpe, V., et al. (2013). Autoimmune Manifestations in the 3xTg-AD Model of Alzheimer's Disease. J. Alzheimers Dis. 39, 191-210. doi: 10.3233/JAD-131490.
216. Markesbery, W. R., Schmitt, F. A., Kryscio, R. J., Davis, D. G., Smith, C. D., and Wekstein, D. R. (2006). Neuropathologic substrate of mild cognitive impairment. Arch. Neurol. 63, 38-46. doi: 10.1001/archneur.63.1.38.
217. Mckee, A. C., Kosik, K. S., and Kowall, N. W. (1991). Neuritic pathology and dementia in Alzheimer's disease. Ann. Neurol. 30, 156-165. doi: 10.1002/ana.410300206.
218. Mckhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R. Jr., Kawas, C. H., et al. (2011). The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 263-269. doi: 10.1016/j.jalz.2011.03.005.
219. Mega, M. S., Cummings, J. L., Fiorello, T., and Gornbein, J. (1996). The spectrum of behavioral changes in Alzheimer's disease. Neurology 46, 130-135. doi: 10.1212/WNL.46.1.130.
220. Meilandt, W. J., Yu, G. Q., Chin, J., Roberson, E. D., Palop, J. J., Wu, T., et al. (2008). Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 28, 5007-5017. doi: 10.1523/JNEUROSCI.0590-08.2008.
221. Meltzer, C. C., Smith, G., Dekosky, S. T., Pollock, B. G., Mathis, C. A., Moore, R. Y., et al. (1998). Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology 18, 407-430. doi: 10.1016/S0893-133X(97)00194-2.
222. Mendez, M. F., Martin, R. J., Smyth, K. A., and Whitehouse, P. J. (1990). Psychiatric symptoms associated with Alzheimer's disease. J. Neuropsychiatry Clin. Neurosci. 2, 28-33.
223. Mickes, L., Wixted, J. T., Fennema-Notestine, C., Galasko, D., Bondi, M. W., Thal, L. J., et al. (2007). Progressive impairment on neuropsychological tasks in a longitudinal study of preclinical Alzheimer's disease. Neuropsychology 21, 696-705. doi: 10.1037/0894-4105.21.6.696.
224. Migliorelli, R., Petracca, G., Teson, A., Sabe, L., Leiguarda, R., and Starkstein, S. E. (1995a). Neuropsychiatric and neuropsychological correlates of delusions in Alzheimer's disease. Psychol. Med. 25, 505-513. doi: 10.1017/S0033291700033420.
225. Migliorelli, R., Teson, A., Sabe, L., Petracchi, M., Leiguarda, R., and Starkstein, S. E. (1995b). Prevalence and correlates of dysthymia and major depression among patients with Alzheimer's disease. Am. J. Psychiatry 152, 37-44.
226. Moechars, D., Dewachter, I., Lorent, K., Reverse, D., Baekelandt, V., Naidu, A., et al. (1999). Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274, 6483-6492. doi: 10.1074/jbc.274.10.6483.
227. Moechars, D., Gilis, M., Kuiperi, C., Laenen, I., and Van Leuven, F. (1998). Aggressive behaviour in transgenic mice expressing APP is alleviated by serotonergic drugs. Neuroreport 9, 3561-3564. doi: 10.1097/00001756-199811160-00004.
228. Moechars, D., Lorent, K., De Strooper, B., Dewachter, I., and Van Leuven, F. (1996). Expression in brain of amyloid precursor protein mutated in the alpha-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. EMBO J. 15, 1265-1274.
229. Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., et al. (2012). National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 123, 1-11. doi: 10.1007/s00401-011-0910-3.
230. Morgan, D. (2003). Learning and memory deficits in APP transgenic mouse models of amyloid deposition. Neurochem. Res. 28, 1029-1034. doi: 10.1023/A:1023255106106.
231. Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., et al. (2000). A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985. doi: 10.1038/35050116.
232. Mori, T., Koyama, N., Guillot-Sestier, M. V., Tan, J., and Town, T. (2013). Ferulic acid is a nutraceutical beta-secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice. PLoS ONE 8:e55774. doi: 10.1371/journal.pone.0055774.
233. Morris, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., Van Belle, G., Fillenbaum, G., et al. (1989). The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39, 1159-1165. doi: 10.1212/WNL.39.9.1159.
234. Morris, R. G. (2001). Episodic-like memory in animals: psychological criteria, neural mechanisms and the value of episodic-like tasks to investigate animal models of neurodegenerative disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356, 1453-1465. doi: 10.1098/rstb.2001.0945.
235. Morris, R. G., Garrud, P., Rawlins, J. N., and O'keefe, J. (1982). Place navigation impaired in rats with hippocampal lesions. Nature 297, 681-683. doi: 10.1038/297681a0.
236. Mucke, L., Masliah, E., Yu, G. Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., et al. (2000). High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050-4058. Available online at: http://www.jneurosci.org/content/20/11/4050.long.
237. Muir, J. L. (1996). Attention and stimulus processing in the rat. Brain Res. Cogn. Brain Res. 3, 215-225. doi: 10.1016/0926-6410(96)00008-0.
238. Mungas, D., Reed, B. R., Ellis, W. G., and Jagust, W. J. (2001). The effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular disease. Arch. Neurol. 58, 1243-1247. doi: 10.1001/archneur.58.8.1243.
239. Murakami, K., Yokoyama, S., Murata, N., Ozawa, Y., Irie, K., Shirasawa, T., et al. (2011). Insulin receptor mutation results in insulin resistance and hyperinsulinemia but does not exacerbate Alzheimer's-like phenotypes in mice. Biochem. Biophys. Res. Commun. 409, 34-39. doi: 10.1016/j.bbrc.2011.04.101.
240. Murman, D. L., Chen, Q., Colucci, P. M., Colenda, C. C., Gelb, D. J., and Liang, J. (2002a). Comparison of healthcare utilization and direct costs in three degenerative dementias. Am. J. Geriatr. Psychiatry 10, 328-336. doi: 10.1097/00019442-200205000-00013.
241. Murman, D. L., Chen, Q., Powell, M. C., Kuo, S. B., Bradley, C. J., and Colenda, C. C. (2002b). The incremental direct costs associated with behavioral symptoms in AD. Neurology 59, 1721-1729. doi: 10.1212/01.WNL.0000036904.73393.E4.
242. Murray, M. E., Graff-Radford, N. R., Ross, O. A., Petersen, R. C., Duara, R., and Dickson, D. W. (2011). Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 10, 785-796. doi: 10.1016/S1474-4422(11)70156-9.
243. Musilli, M., Nicolia, V., Borrelli, S., Scarpa, S., and Diana, G. (2013). Behavioral effects of Rho GTPase modulation in a model of Alzheimer's disease. Behav. Brain Res. 237, 223-229. doi: 10.1016/j.bbr.2012.09.043.
244. Nagy, Z., Esiri, M. M., Jobst, K. A., Morris, J. H., King, E. M., Mcdonald, B., et al. (1995). Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia 6, 21-31.
245. Nagy, Z., Hindley, N. J., Braak, H., Braak, E., Yilmazer-Hanke, D. M., Schultz, C., et al. (1999). The progression of Alzheimer's disease from limbic regions to the neocortex: clinical, radiological and pathological relationships. Dement. Geriatr. Cogn. Disord. 10, 115-120. doi: 10.1159/000017111.
246. Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., et al. (2005). The Montreal Cognitive Assessment (MoCA): a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695-699. doi: 10.1111/j.1532-5415.2005.53221.x.
247. Nelson, P. T., Abner, E. L., Scheff, S. W., Schmitt, F. A., Kryscio, R. J., Jicha, G. A., et al. (2009a). Alzheimer's-type neuropathology in the precuneus is not increased relative to other areas of neocortex across a range of cognitive impairment. Neurosci. Lett. 450, 336-339. doi: 10.1016/j.neulet.2008.11.006.
248. Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., et al. (2012). Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 71, 362-381. doi: 10.1097/NEN.0b013e31825018f7.
249. Nelson, P. T., Braak, H., and Markesbery, W. R. (2009b). Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J. Neuropathol. Exp. Neurol. 68, 1-14. doi: 10.1097/NEN.0b013e3181919a48.
250. Nelson, P. T., Jicha, G. A., Schmitt, F. A., Liu, H., Davis, D. G., Mendiondo, M. S., et al. (2007a). Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J. Neuropathol. Exp. Neurol. 66, 1136-1146. doi: 10.1097/nen.0b013e31815c5efb.
251. Nelson, R. L., Guo, Z., Halagappa, V. M., Pearson, M., Gray, A. J., Matsuoka, Y., et al. (2007b). Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp. Neurol. 205, 166-176. doi: 10.1016/j.expneurol.2007.01.037.
252. Nestler, E. J., and Hyman, S. E. (2010). Animal models of neuropsychiatric disorders. Nat. Neurosci. 13, 1161-1169. doi: 10.1038/nn.2647.
253. Nilsson, L. N., Arendash, G. W., Leighty, R. E., Costa, D. A., Low, M. A., Garcia, M. F., et al. (2004). Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. Neurobiol. Aging 25, 1153-1167. doi: 10.1016/j.neurobiolaging.2003.12.011.
254. O'leary, T. P., and Brown, R. E. (2009). Visuo-spatial learning and memory deficits on the Barnes maze in the 16-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease. Behav. Brain Res. 201, 120-127. doi: 10.1016/j.bbr.2009.01.039.
255. Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., et al. (2006). Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129-10140. doi: 10.1523/JNEUROSCI.1202-06.2006.
256. Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., et al. (2003). Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421. doi: 10.1016/S0896-6273(03)00434-3.
257. Ognibene, E., Middei, S., Daniele, S., Adriani, W., Ghirardi, O., Caprioli, A., et al. (2005). Aspects of spatial memory and behavioral disinhibition in Tg2576 transgenic mice as a model of Alzheimer's disease. Behav. Brain Res. 156, 225-232. doi: 10.1016/j.bbr.2004.05.028.
258. Ohno, M., Chang, L., Tseng, W., Oakley, H., Citron, M., Klein, W. L., et al. (2006). Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur. J. Neurosci. 23, 251-260. doi: 10.1111/j.1460-9568.2005.04551.x.
259. Ohno, M., Sametsky, E. A., Younkin, L. H., Oakley, H., Younkin, S. G., Citron, M., et al. (2004). BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41, 27-33. doi: 10.1016/S0896-6273(03)00810-9.
260. Okawa, M., Mishima, K., Hishikawa, Y., Hozumi, S., Hori, H., and Takahashi, K. (1991). Circadian rhythm disorders in sleep-waking and body temperature in elderly patients with dementia and their treatment. Sleep 14, 478-485.
261. Olton, D. S., Becker, J. T., and Handelmann, G. E. (1979). Hippocampus, Space, and Memory. Behav. Brain Sci. 2, 313-322. doi: 10.1017/S0140525X00062713.
262. Olton, D. S., and Feustle, W. A. (1981). Hippocampal function required for nonspatial working memory. Exp. Brain Res. 41, 380-389.
263. Olton, D. S., and Samuelson, R. J. (1976). Remembrance of Places Passed - Spatial Memory in Rats. J. Exp. Psychol. Anim. Behav. Process. 2, 97-116. doi: 10.1037/0097-7403.2.2.97.
264. Oules, B., Del Prete, D., Greco, B., Zhang, X., Lauritzen, I., Sevalle, J., et al. (2012). Ryanodine receptor blockade reduces amyloid-beta load and memory impairments in Tg2576 mouse model of Alzheimer disease. J. Neurosci. 32, 11820-11834. doi: 10.1523/JNEUROSCI.0875-12.2012.
265. Ownby, R. L., Crocco, E., Acevedo, A., John, V., and Loewenstein, D. (2006). Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch. Gen. Psychiatry 63, 530-538. doi: 10.1001/archpsyc.63.5.530.
266. Palop, J. J., Jones, B., Kekonius, L., Chin, J., Yu, G. Q., Raber, J., et al. (2003). Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl. Acad. Sci. U.S.A. 100, 9572-9577. doi: 10.1073/pnas.1133381100.
267. Papadopoulos, P., Rosa-Neto, P., Rochford, J., and Hamel, E. (2013). Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-beta and cerebrovascular pathology. PLoS ONE 8:e68612. doi: 10.1371/journal.pone.0068612.
268. Parasuraman, R., and Nestor, P. (1993). Attention and driving. Assessment in elderly individuals with dementia. Clin. Geriatr. Med. 9, 377-387.
269. Park, J. H., Widi, G. A., Gimbel, D. A., Harel, N. Y., Lee, D. H., and Strittmatter, S. M. (2006). Subcutaneous Nogo receptor removes brain amyloid-beta and improves spatial memory in Alzheimer's transgenic mice. J. Neurosci. 26, 13279-13286. doi: 10.1523/JNEUROSCI.4504-06.2006.
270. Pattij, T., Janssen, M. C., Loos, M., Smit, A. B., Schoffelmeer, A. N., and Van Gaalen, M. M. (2007). Strain specificity and cholinergic modulation of visuospatial attention in three inbred mouse strains. Genes Brain Behav. 6, 579-587. doi: 10.1111/j.1601-183X.2006.00284.x.
271. Pearlson, G. D., Ross, C. A., Lohr, W. D., Rovner, B. W., Chase, G. A., and Folstein, M. F. (1990). Association between family history of affective-disorder and the depressive syndrome of Alzheimers-disease. Am. J. Psychiatry 147, 452-456.
272. Perry, R. J., and Hodges, J. R. (1999). Attention and executive deficits in Alzheimer's disease. A critical review. Brain 122(Pt 3), 383-404. doi: 10.1093/brain/122.3.383.
273. Perry, R. J., Watson, P., and Hodges, J. R. (2000). The nature and staging of attention dysfunction in early (minimal and mild) Alzheimer's disease: relationship to episodic and semantic memory impairment. Neuropsychologia 38, 252-271. doi: 10.1016/S0028-3932(99)00079-2.
274. Pietropaolo, S., Feldon, J., and Yee, B. K. (2008). Age-dependent phenotypic characteristics of a triple transgenic mouse model of Alzheimer disease. Behav. Neurosci. 122, 733-747. doi: 10.1037/a0012520.
275. Platt, T. L., Reeves, V. L., and Murphy, M. P. (2013). Transgenic models of Alzheimer's disease: better utilization of existing models through viral transgenesis. Biochim. Biophys. Acta 1832, 1437-1448. doi: 10.1016/j.bbadis.2013.04.017.
276. Prut, L., Abramowski, D., Krucker, T., Levy, C. L., Roberts, A. J., Staufenbiel, M., et al. (2007). Aged APP23 mice show a delay in switching to the use of a strategy in the Barnes maze. Behav. Brain Res. 179, 107-110. doi: 10.1016/j.bbr.2007.01.017.
277. Pugh, P. L., Richardson, J. C., Bate, S. T., Upton, N., and Sunter, D. (2007). Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer's disease. Behav. Brain Res. 178, 18-28. doi: 10.1016/j.bbr.2006.11.044.
278. Reiserer, R. S., Harrison, F. E., Syverud, D. C., and Mcdonald, M. P. (2007). Impaired spatial learning in the APPSwe + PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav. 6, 54-65. doi: 10.1111/j.1601-183X.2006.00221.x.
279. Richter, H., Ambree, O., Lewejohann, L., Herring, A., Keyvani, K., Paulus, W., et al. (2008). Wheel-running in a transgenic mouse model of Alzheimer's disease: protection or symptom? Behav. Brain Res. 190, 74-84. doi: 10.1016/j.bbr.2008.02.005.
280. Riley, K. P., Jicha, G. A., Davis, D., Abner, E. L., Cooper, G. E., Stiles, N., et al. (2011). Prediction of preclinical Alzheimer's disease: longitudinal rates of change in cognition. J. Alzheimers Dis. 25, 707-717. doi: 10.3233/JAD-2011-102133.
281. Riley, K. P., Snowdon, D. A., and Markesbery, W. R. (2002). Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study. Ann. Neurol. 51, 567-577. doi: 10.1002/ana.10161.
282. Robbins, T. W. (1996). Dissociating executive functions of the prefrontal cortex. Philos. Trans. R. Soc. Lond. B Biol. Sci. 351, 1463-1470. discussion: 1470-1461. doi: 10.1098/rstb.1996.0131.
283. Robbins, T. W. (2002). The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl.) 163, 362-380. doi: 10.1007/s00213-002-1154-7.
284. Robinson, A. L., Heaton, R. K., Lehman, R. A., and Stilson, D. W. (1980). The utility of the Wisconsin Card Sorting Test in detecting and localizing frontal lobe lesions. J. Consult. Clin. Psychol. 48, 605-614. doi: 10.1037/0022-006X.48.5.605.
285. Robinson, J. K., and Crawley, J. N. (1993). Intraventricular galanin impairs delayed nonmatching-to-sample performance in rats. Behav. Neurosci. 107, 458-467. doi: 10.1037/0735-7044.107.3.458.
286. Robinson, J. L., Geser, F., Corrada, M. M., Berlau, D. J., Arnold, S. E., Lee, V. M., et al. (2011). Neocortical and hippocampal amyloid-beta and tau measures associate with dementia in the oldest-old. Brain 134, 3708-3715. doi: 10.1093/brain/awr308.
287. Romberg, C., Bussey, T. J., and Saksida, L. M. (2013a). Paying more attention to attention: towards more comprehensive cognitive translation using mouse models of Alzheimer's disease. Brain Res. Bull. 92, 49-55. doi: 10.1016/j.brainresbull.2012.02.007.
288. Romberg, C., Horner, A. E., Bussey, T. J., and Saksida, L. M. (2013b). A touch screen-automated cognitive test battery reveals impaired attention, memory abnormalities, and increased response inhibition in the TgCRND8 mouse model of Alzheimer's disease. Neurobiol. Aging 34, 731-744. doi: 10.1016/j.neurobiolaging.2012.08.006.
289. Romberg, C., Mattson, M. P., Mughal, M. R., Bussey, T. J., and Saksida, L. M. (2011). Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept). J. Neurosci. 31, 3500-3507. doi: 10.1523/JNEUROSCI.5242-10.2011.
290. Rosen, C., Hansson, O., Blennow, K., and Zetterberg, H. (2013). Fluid biomarkers in Alzheimer's disease - current concepts. Mol. Neurodegener. 8:20. doi: 10.1186/1750-1326-8-20.
291. Rosen, C., and Zetterberg, H. (2013). Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease. Curr. Opin. Psychiatry 26, 276-282. doi: 10.1097/YCO.0b013e32835f6747.
292. Rosen, W. G., Mohs, R. C., and Davis, K. L. (1984). A new rating scale for Alzheimer's disease. Am. J. Psychiatry 141, 1356-1364.
293. Sabbagh, M. N., Cooper, K., Delange, J., Stoehr, J. D., Thind, K., Lahti, T., et al. (2010). Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD. Curr. Alzheimer Res. 7, 280-286. doi: 10.2174/156720510791162340.
294. Sabbagh, M. N., Corey-Bloom, J., Tiraboschi, P., Thomas, R., Masliah, E., and Thal, L. J. (1999). Neurochemical markers do not correlate with cognitive decline in the Lewy body variant of Alzheimer disease. Arch. Neurol. 56, 1458-1461. doi: 10.1001/archneur.56.12.1458.
295. Sadowski, M., Pankiewicz, J., Scholtzova, H., Ji, Y., Quartermain, D., Jensen, C. H., et al. (2004). Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice. J. Neuropathol. Exp. Neurol. 63, 418-428. Available online at: http://journals.lww.com/jneuropath/Pages/default.aspx.
296. Salmon, D. P., and Bondi, M. W. (2009). Neuropsychological assessment of dementia. Annu. Rev. Psychol. 60, 257-282. doi: 10.1146/annurev.psych.57.102904.190024.
297. Salmon, D. P., Heindel, W. C., and Lange, K. L. (1999). Differential decline in word generation from phonemic and semantic categories during the course of Alzheimer's disease: implications for the integrity of semantic memory. J. Int. Neuropsychol. Soc. 5, 692-703. doi: 10.1017/S1355617799577126.
298. Salmon, D. P., Thomas, R. G., Pay, M. M., Booth, A., Hofstetter, C. R., Thal, L. J., et al. (2002). Alzheimer's disease can be accurately diagnosed in very mildly impaired individuals. Neurology 59, 1022-1028. doi: 10.1212/WNL.59.7.1022.
299. Sanchez-Mejia, R. O., Newman, J. W., Toh, S., Yu, G. Q., Zhou, Y., Halabisky, B., et al. (2008). Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat. Neurosci. 11, 1311-1318. doi: 10.1038/nn.2213.
300. Santacruz, K. S., Sonnen, J. A., Pezhouh, M. K., Desrosiers, M. F., Nelson, P. T., and Tyas, S. L. (2011). Alzheimer disease pathology in subjects without dementia in 2 studies of aging: the Nun Study and the Adult Changes in Thought Study. J. Neuropathol. Exp. Neurol. 70, 832-840. doi: 10.1097/NEN.0b013e31822e8ae9.
301. Satlin, A., Volicer, L., Stopa, E. G., and Harper, D. (1995). Circadian locomotor activity and core-body temperature rhythms in Alzheimer's disease. Neurobiol. Aging 16, 765-771. doi: 10.1016/0197-4580(95)00059-N.
302. Saura, C. A., Chen, G., Malkani, S., Choi, S. Y., Takahashi, R. H., Zhang, D., et al. (2005). Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J. Neurosci. 25, 6755-6764. doi: 10.1523/JNEUROSCI.1247-05.2005.
303. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., et al. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177. doi: 10.1038/22124.
304. Schmitt, F. A., Davis, D. G., Wekstein, D. R., Smith, C. D., Ashford, J. W., and Markesbery, W. R. (2000). "Preclinical" AD revisited: neuropathology of cognitively normal older adults. Neurology 55, 370-376. doi: 10.1212/WNL.55.3.370.
305. Schmitt, F. A., and Wichems, C. H. (2006). A systematic review of assessment and treatment of moderate to severe Alzheimer's disease. Prim. Care Companion J. Clin. Psychiatry 8, 158-159. doi: 10.4088/PCC.v08n0306.
306. Schmitt, F. S. M. (1994). Handbook of Dementing Illnesses. New York, NY: Marcel Dekker, Inc.
307. Seligman, M. E., Rosellini, R. A., and Kozak, M. J. (1975). Learned helplessness in the rat: time course, immunization, and reversibility. J. Comp. Physiol. Psychol. 88, 542-547. doi: 10.1037/h0076431.
308. Senanarong, V., Cummings, J. L., Fairbanks, L., Mega, M., Masterman, D. M., O'connor, S. M., et al. (2004). Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction. Dement. Geriatr. Cogn. Disord. 17, 14-20. doi: 10.1159/000074080.
309. Shin, I. S., Carter, M., Masterman, D., Fairbanks, L., and Cummings, J. L. (2005). Neuropsychiatric symptoms and quality of life in Alzheimer disease. Am. J. Geriatr. Psychiatry 13, 469-474. doi: 10.1097/00019442-200506000-00005.
310. Shukla, V., Zheng, Y. L., Mishra, S. K., Amin, N. D., Steiner, J., Grant, P., et al. (2013). A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice. FASEB J. 27, 174-186. doi: 10.1096/fj.12-217497.
311. Silver, M. H., Newell, K., Brady, C., Hedley-White, E. T., and Perls, T. T. (2002). Distinguishing between neurodegenerative disease and disease-free aging: correlating neuropsychological evaluations and neuropathological studies in centenarians. Psychosom. Med. 64, 493-501.
312. Simard, M., and Van Reekum, R. (1999). Memory assessment in studies of cognition-enhancing drugs for Alzheimer's disease. Drugs Aging 14, 197-230. doi: 10.2165/00002512-199914030-00004.
313. Simon, A. M., Schiapparelli, L., Salazar-Colocho, P., Cuadrado-Tejedor, M., Escribano, L., Lopez De Maturana, R., et al. (2009). Overexpression of wild-type human APP in mice causes cognitive deficits and pathological features unrelated to Abeta levels. Neurobiol. Dis. 33, 369-378. doi: 10.1016/j.nbd.2008.11.005.
314. Smith, C. (1985). Sleep states and learning: a review of the animal literature. Neurosci. Biobehav. Rev. 9, 157-168. doi: 10.1016/0149-7634(85)90042-9.
315. Smith, G. E., Pankratz, V. S., Negash, S., Machulda, M. M., Petersen, R. C., Boeve, B. F., et al. (2007). A plateau in pre-Alzheimer memory decline: evidence for compensatory mechanisms? Neurology 69, 133-139. doi: 10.1212/01.wnl.0000265594.23511.16.
316. Snyderman, D., and Rovner, B. (2009). Mental status exam in primary care: a review. Am. Fam. Physician 80, 809-814. Available online at: http://www.aafp.org/afp/2009/1015/p809.
317. Song, C., and Leonard, B. E. (2005). The olfactory bulbectomised rat as a model of depression. Neurosci. Biobehav. Rev. 29, 627-647. doi: 10.1016/j.neubiorev.2005.03.010.
318. Sood, A., Warren Beach, J., Webster, S. J., Terry, A. V., and Buccafusco, J. J. (2007). The effects of JWB1-84-1 on memory-related task performance by amyloid Abeta transgenic mice and by young and aged monkeys. Neuropharmacology 53, 588-600. doi: 10.1016/j.neuropharm.2007.06.028.
319. Spreen, O., and Strauss, E. (1998). A compendium of neuropsychological tests, 2nd Edn. New York, NY: Oxford University Press.
320. Sterniczuk, R., Dyck, R. H., Laferla, F. M., and Antle, M. C. (2010). Characterization of the 3xTg-AD mouse model of Alzheimer's disease: Part 1. Circadian changes. Brain Res. 1348, 139-148. doi: 10.1016/j.brainres.2010.05.013.
321. Stewart, S., Cacucci, F., and Lever, C. (2011). Which memory task for my mouse? A systematic review of spatial memory performance in the Tg2576 Alzheimer's mouse model. J. Alzheimers Dis. 26, 105-126. doi: 10.3233/JAD-2011-101827.
322. Stopford, C. L., Thompson, J. C., Neary, D., Richardson, A. M., and Snowden, J. S. (2012). Working memory, attention, and executive function in Alzheimer's disease and frontotemporal dementia. Cortex 48, 429-446. doi: 10.1016/j.cortex.2010.12.002.
323. Storandt, M. (1991). Neuropsychological assessment in Alzheimer's disease. Exp. Aging Res. 17, 100-101.
324. Storandt, M., Grant, E. A., Miller, J. P., and Morris, J. C. (2006). Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology 67, 467-473. doi: 10.1212/01.wnl.0000228231.26111.6e.
325. Storandt, M., and Hill, R. D. (1989). Very mild senile dementia of the Alzheimer type. II. Psychometric test performance. Arch. Neurol. 46, 383-386. doi: 10.1001/archneur.1989.00520400037017.
326. Storandt, M., Kaskie, B., and Von Dras, D. D. (1998). Temporal memory for remote events in healthy aging and dementia. Psychol. Aging 13, 4-7. doi: 10.1037/0882-7974.13.1.4.
327. Strauss, M. E., and Ogrocki, P. K. (1996). Confirmation of an association between family history of affective disorder and the depressive syndrome in Alzheimer's disease. Am. J. Psychiatry 153, 1340-1342.
328. Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K. H., Mistl, C., Rothacher, S., et al. (1997). Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U.S.A. 94, 13287-13292. doi: 10.1073/pnas.94.24.13287.
329. Tan, L. L., Wong, H. B., and Allen, H. (2005). The impact of neuropsychiatric symptoms of dementia on distress in family and professional caregivers in Singapore. Int. Psychogeriatr. 17, 253-263. doi: 10.1017/S1041610205001523.
330. Thal, D. R., Rub, U., Orantes, M., and Braak, H. (2002). Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791-1800. doi: 10.1212/WNL.58.12.1791.
331. Thibault, O., Pancani, T., Landfield, P. W., and Norris, C. M. (2012). Reduction in neuronal L-type calcium channel activity in a double knock-in mouse model of Alzheimer's disease. Biochim. Biophys. Acta 1822, 546-549. doi: 10.1016/j.bbadis.2012.01.004.
332. Tiraboschi, P., Hansen, L. A., Alford, M., Merdes, A., Masliah, E., Thal, L. J., et al. (2002). Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch. Gen. Psychiatry 59, 946-951. doi: 10.1001/archpsyc.59.10.946.
333. Tiraboschi, P., Hansen, L. A., Thal, L. J., and Corey-Bloom, J. (2004). The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 62, 1984-1989. doi: 10.1212/01.WNL.0000129697.01779.0A.
334. Tohda, C., Urano, T., Umezaki, M., Nemere, I., and Kuboyama, T. (2012). Diosgenin is an exogenous activator of 1,25D(3)-MARRS/Pdia3/ERp57 and improves Alzheimer's disease pathologies in 5XFAD mice. Sci. Rep. 2:535. doi: 10.1038/srep00535.
335. Tomlinson, B. E., Blessed, G., and Roth, M. (1970). Observations on the brains of demented old people. J. Neurol. Sci. 11, 205-242. doi: 10.1016/0022-510X(70)90063-8.
336. Trinchese, F., Liu, S., Battaglia, F., Walter, S., Mathews, P. M., and Arancio, O. (2004). Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann. Neurol. 55, 801-814. doi: 10.1002/ana.20101.
337. Tulving, E., and Markowitsch, H. J. (1998). Episodic and declarative memory: role of the hippocampus. Hippocampus 8, 198-204.
338. Tuokko, H., Morris, C., and Ebert, P. (2005). Mild cognitive impairment and everyday functioning in older adults. Neurocase 11, 40-47. doi: 10.1080/13554790490896802.
339. Twamley, E. W., Ropacki, S. A. L., and Bondi, M. W. (2006). Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease. J. Int. Neuropsychol. Soc. 12, 707-735. doi: 10.1017/S1355617706060863.
340. Urano, T., and Tohda, C. (2010). Icariin improves memory impairment in Alzheimer's disease model mice (5xFAD) and attenuates amyloid beta-induced neurite atrophy. Phytother. Res. 24, 1658-1663. doi: 10.1002/ptr.3183.
341. Van Dam, D., D'hooge, R., Staufenbiel, M., Van Ginneken, C., Van Meir, F., and De Deyn, P. P. (2003). Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur. J. Neurosci. 17, 388-396. doi: 10.1046/j.1460-9568.2003.02444.x.
342. Van Der Poel, A. M. (1967). Ethological study of the behaviour of the albino rat in a passive-avoidance test. Acta Physiol. Pharmacol. Neerl. 14, 503-505.
343. Van Dorpe, J., Smeijers, L., Dewachter, I., Nuyens, D., Spittaels, K., Van Den Haute, C., et al. (2000). Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. Am. J. Pathol. 157, 1283-1298. doi: 10.1016/S0002-9440(10)64644-5.
344. Van Someren, E. J., Hagebeuk, E. E., Lijzenga, C., Scheltens, P., De Rooij, S. E., Jonker, C., et al. (1996). Circadian rest-activity rhythm disturbances in Alzheimer's disease. Biol. Psychiatry 40, 259-270. doi: 10.1016/0006-3223(95)00370-3.
345. Vanderwolf, C. H. (1964). Effect of combined medial thalamic and septal lesions on active-avoidance behavior. J. Comp. Physiol. Psychol. 58, 31-37. doi: 10.1037/h0042400.
346. Vitiello, M. V., Bliwise, D. L., and Prinz, P. N. (1992). Sleep in Alzheimer's disease and the sundown syndrome. Neurology 42, 83-93. discussion: 93-84.
347. Vloeberghs, E., Van Dam, D., Coen, K., Staufenbiel, M., and De Deyn, P. P. (2006). Aggressive male APP23 mice modeling behavioral alterations in dementia. Behav. Neurosci. 120, 1380-1383. doi: 10.1037/0735-7044.120.6.1380.
348. Vloeberghs, E., Van Dam, D., Engelborghs, S., Nagels, G., Staufenbiel, M., and De Deyn, P. P. (2004). Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances. Eur. J. Neurosci. 20, 2757-2766. doi: 10.1111/j.1460-9568.2004.03755.x.
349. Volianskis, A., Kostner, R., Molgaard, M., Hass, S., and Jensen, M. S. (2010). Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe/PS1deltaE9-deleted transgenic mice model of ss-amyloidosis. Neurobiol. Aging 31, 1173-1187. doi: 10.1016/j.neurobiolaging.2008.08.005.
350. Webster, S. J., Bachstetter, A. D., and Van Eldik, L. J. (2013). Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's disease. Alzheimers. Res. Ther. 5, 28. doi: 10.1186/alzrt182.
351. Wechsler, D. (1997). Wechsler Memory Scale. 3rd Edition Manual. San Antonio, TX: The Psychological Corperation.
352. Weinberger, D. R., Berman, K. F., and Zec, R. F. (1986). Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch. Gen. Psychiatry 43, 114-124. doi: 10.1001/archpsyc.1986.01800020020004.
353. Weintraub, S., Wicklund, A. H., and Salmon, D. P. (2012). The neuropsychological profile of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2:a006171. doi: 10.1101/cshperspect.a006171.
354. Welsh, K., Butters, N., Hughes, J., Mohs, R., and Heyman, A. (1991). Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures. Arch. Neurol. 48, 278-281. doi: 10.1001/archneur.1991.00530150046016.
355. Welsh, K. A., Butters, N., Hughes, J. P., Mohs, R. C., and Heyman, A. (1992). Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the consortium to establish a registry for Alzheimer's Disease. Arch. Neurol. 49, 448-452. doi: 10.1001/archneur.1992.00530290030008.
356. Westerman, M. A., Cooper-Blacketer, D., Mariash, A., Kotilinek, L., Kawarabayashi, T., Younkin, L. H., et al. (2002). The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22, 1858-1867. Available online at: http://www.jneurosci.org/content/22/5/1858.long.
357. Whitwell, J. L., Josephs, K. A., Murray, M. E., Kantarci, K., Przybelski, S. A., Weigand, S. D., et al. (2008). MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 71, 743-749. doi: 10.1212/01.wnl.0000324924.91351.7d.
358. Wilcock, D. M., Rojiani, A., Rosenthal, A., Subbarao, S., Freeman, M. J., Gordon, M. N., et al. (2004). Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation 1:24. doi: 10.1186/1742-2094-1-24.
359. Wilkinson, R. T. (1963). Interaction of noise with knowledge of results and sleep deprivation. J. Exp. Psychol. 66, 332-337. doi: 10.1037/h0044161.
360. Wisor, J. P., Edgar, D. M., Yesavage, J., Ryan, H. S., Mccormick, C. M., Lapustea, N., et al. (2005). Sleep and circadian abnormalities in a transgenic mouse model of Alzheimer's disease: a role for cholinergic transmission. Neuroscience 131, 375-385. doi: 10.1016/j.neuroscience.2004.11.018.
361. Yassine, N., Lazaris, A., Dorner-Ciossek, C., Despres, O., Meyer, L., Maitre, M., et al. (2013). Detecting spatial memory deficits beyond blindness in tg2576 Alzheimer mice. Neurobiol. Aging 34, 716-730. doi: 10.1016/j.neurobiolaging.2012.06.016.
362. Young, J. W., Light, G. A., Marston, H. M., Sharp, R., and Geyer, M. A. (2009). The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PLoS ONE 4:e4227. doi: 10.1371/journal.pone.0004227.
363. Zhang, W., Hao, J., Liu, R., Zhang, Z., Lei, G., Su, C., et al. (2011). Soluble Abeta levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease. Behav. Brain Res. 222, 342-350. doi: 10.1016/j.bbr.2011.03.072.
364. Zhuo, J. M., Prakasam, A., Murray, M. E., Zhang, H. Y., Baxter, M. G., Sambamurti, K., et al. (2008). An increase in Abeta42 in the prefrontal cortex is associated with a reversal-learning impairment in Alzheimer's disease model Tg2576 APPsw mice. Curr. Alzheimer Res. 5, 385-391. doi: 10.2174/156720508785132280.
365. Zhuo, J. M., Prescott, S. L., Murray, M. E., Zhang, H. Y., Baxter, M. G., and Nicolle, M. M. (2007). Early discrimination reversal learning impairment and preserved spatial learning in a longitudinal study of Tg2576 APPsw mice. Neurobiol. Aging 28, 1248-1257. doi: 10.1016/j.neurobiolaging.2006.05.034.